Hematology Clinical Trials

Statistical methods in hematology trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All hematology trials

378 results

• Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 21NCT03311126
• Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin’s Lymphoma(NHL): Complete Statistical AnalysisIndependent statistical analysis of Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00426855).Phase 1/2Results postedn = 12NCT00426855
• Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00705250).Phase 2Results postedn = 36NCT00705250
• Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 45NCT00891839
• Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 24NCT02224729
• Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL): Complete Statistical AnalysisIndependent statistical analysis of Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 27NCT02433795
• BENEGENE-2Independent statistical analysis of A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B: primary endpoint results,…Phase 3Results postedn = 51NCT03861273
• BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 3Results postedn = 2NCT02417129
• BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL): Complete Statistical AnalysisIndependent statistical analysis of BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01296932).Phase 1Results postedn = 37NCT01296932
• Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor: Complete Statistical AnalysisIndependent statistical analysis of Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 3NCT01598025
• Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts: Complete Statistical AnalysisIndependent statistical analysis of Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1/2Results postedn = 16NCT03160079
• Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 3Results postedn = 669NCT02101853
• Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission: Complete Statistical AnalysisIndependent statistical analysis of Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 63NCT01096602
• Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor: Complete Statistical AnalysisIndependent statistical analysis of Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 28NCT01350245
• BortezomibIndependent statistical analysis of Bortezomib to Treat Significant Complication of HSCT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01929980).Phase 2Results postedn = 4NCT01929980
• Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 148NCT00873093
• Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 52NCT00666588
• Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00869323).Phase 2Results postedn = 3NCT00869323
• Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 1,645NCT01371981
• Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 15NCT01891968
• Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 6NCT01465386
• Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00075881).Phase 2Results postedn = 44NCT00075881
• Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL): Complete Statistical AnalysisIndependent statistical analysis of Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00440726).Phase 1/2Results postedn = 31NCT00440726
• Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma: primary endpoint results, effect estimate with confidence…Phase 2Results postedn = 45NCT00458705
• Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin’s Lymphoma That is Recurrent or Did Not Respond to Previous Therapy: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy: primary endpoint results, effect estimate with…Phase 2Results postedn = 26NCT00381940
• BOSTONIndependent statistical analysis of the phase 3 BOSTON trial of selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in multiple myeloma, including PFS, response, overall survival, safety, and statistical methodology.Phase 3Results postedn = 402NCT03110562
• BretuximabIndependent statistical analysis of Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 25NCT02388490
• BRIGHT AML1019Independent statistical analysis of A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia: primary endpoint results, effect estimate…Phase 3Results postedn = 730NCT03416179
• BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL): Complete Statistical AnalysisIndependent statistical analysis of BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL): primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 41NCT03520920
• Busulfan and Cyclophosphamide Followed By ALLO BMT: Complete Statistical AnalysisIndependent statistical analysis of Busulfan and Cyclophosphamide Followed By ALLO BMT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01685411).Phase NAResults postedn = 5NCT01685411
• Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide: Complete Statistical AnalysisIndependent statistical analysis of Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00800839).Phase 2Results postedn = 56NCT00800839
• Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT): Complete Statistical AnalysisIndependent statistical analysis of Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00361140).Phase 4Results postedn = 72NCT00361140
• Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 1/2Results postedn = 50NCT00943319
• Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 71NCT00941720
• BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03264131).Phase 2Results postedn = 16NCT03264131
• CAPTIVATEIndependent statistical analysis of CAPTIVATE (NCT02910583), a randomized phase 2 trial of ibrutinib plus venetoclax in treatment-naive chronic lymphocytic leukemia and small lymphocytic lymphoma, including its primary endpoints, statistical methods, and interpretation.Phase 2Results postedn = 323NCT02910583
• Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment: Complete Statistical AnalysisIndependent statistical analysis of Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00447694).Phase 2Results postedn = 30NCT00447694
• Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation: Complete Statistical AnalysisIndependent statistical analysis of Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1/2Results postedn = 45NCT01690143
• Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1/2Results postedn = 53NCT01029054
• CARTITUDE-1An independent statistical analysis of CARTITUDE-1, evaluating JNJ-68284528, a BCMA-directed CAR-T therapy in participants with relapsed or refractory multiple myeloma.Phase 1/2Results postedn = 126NCT03548207
• Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors: Complete Statistical AnalysisIndependent statistical analysis of Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02717507).Phase 2Results postedn = 196NCT02717507
• CASSIOPEIAA complete statistical analysis of the phase 3 CASSIOPEIA trial evaluating daratumumab in transplant-eligible participants with previously untreated multiple myeloma, including trial design, primary endpoints, reported statistical analyses, safety, and interpretation.Phase 3Results postedn = 1,085NCT02541383
• CBGJ398XUS04Independent statistical analysis of BGJ398 for Patients With Tumors With FGFR Genetic Alterations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02160041).Phase 2Results postedn = 84NCT02160041
• CC-5013 (Lenalidomide) and Rituximab in Waldenstrom’s Macroglobulinemia: Complete Statistical AnalysisIndependent statistical analysis of CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00142168).Phase 2Results postedn = 16NCT00142168
• CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR: Complete Statistical AnalysisIndependent statistical analysis of CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR: primary endpoint results, effect estimate with confidence interval,…Phase NAResults postedn = 1NCT03152526
• CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 2Results postedn = 18NCT02424968
• CHAMPION 1Independent statistical analysis of A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1/2Results postedn = 116NCT01677858
• CHAMPION 2Independent statistical analysis of A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1Results postedn = 22NCT01980589
• Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant: primary endpoint results,…Phase 1/2Results postedn = 35NCT03192397
• Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 11NCT01438177

← All therapeutic areas